Corbus Pharmaceuticals Holdings, Inc.
CRBP
$10.09
$0.010.10%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 105.27% | 26.70% | 109.47% | 93.01% | 121.22% |
| Gross Profit | -105.27% | -26.70% | -109.47% | -93.01% | -121.22% |
| SG&A Expenses | 26.48% | 8.52% | -6.76% | -24.27% | -3.83% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 88.96% | 22.90% | 74.26% | 57.48% | 74.30% |
| Operating Income | -88.96% | -22.90% | -74.26% | -57.48% | -74.30% |
| Income Before Tax | -98.38% | -35.29% | -115.69% | -69.35% | -76.67% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -98.38% | -35.29% | -115.69% | -69.35% | -76.67% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -98.38% | -35.29% | -115.69% | -69.35% | -76.67% |
| EBIT | -88.96% | -22.90% | -74.26% | -57.48% | -74.30% |
| EBITDA | -89.22% | -23.16% | -75.74% | -58.71% | -76.22% |
| EPS Basic | -25.12% | 11.75% | -59.37% | -65.32% | -59.54% |
| Normalized Basic EPS | -25.12% | 11.75% | -18.26% | -65.33% | -59.53% |
| EPS Diluted | -25.12% | 11.75% | -59.37% | -65.32% | -59.54% |
| Normalized Diluted EPS | -25.12% | 11.75% | -18.26% | -65.33% | -59.53% |
| Average Basic Shares Outstanding | 58.55% | 53.31% | 35.33% | 2.44% | 10.74% |
| Average Diluted Shares Outstanding | 58.55% | 53.31% | 35.33% | 2.44% | 10.74% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |